Activated Protein C for Ischemic Central Retinal Vein Occlusion: One-Year Results

Chikako Hara; Motohiro Kamei; Hirokazu Sakaguchi; Nagakazu Matsumura; Susumu Sakimoto; Mihoko Suzuki; Kentaro Nishida; Yoko Fukushima; Kohji Nishida

doi:10.1016/j.oret.2018.07.012

Activated Protein C for Ischemic Central Retinal Vein Occlusion: One-Year Results

Ophthalmol Retina. 2019 Jan;3(1):93-94. doi: 10.1016/j.oret.2018.07.012. Epub 2018 Jul 25.

Authors

Chikako Hara¹, Motohiro Kamei², Hirokazu Sakaguchi¹, Nagakazu Matsumura¹, Susumu Sakimoto¹, Mihoko Suzuki¹, Kentaro Nishida¹, Yoko Fukushima¹, Kohji Nishida¹

Affiliations

¹ Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan.
² Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan; Department of Ophthalmology, Aichi Medical University, Aichi, Japan. Electronic address: motokamei@gmail.com.

PMID: 30935661
DOI: 10.1016/j.oret.2018.07.012

Abstract

Intravitreally administered activated protein C in 10 eyes with ischemic central retinal vein occlusion significantly improved macular edema; in 5 eyes, the reperfusion of the retinal nonperfused areas exceeded 50% of baseline.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Female
Fibrinolytic Agents
Fluorescein Angiography
Follow-Up Studies
Humans
Intravitreal Injections
Macular Edema / diagnosis
Macular Edema / drug therapy*
Macular Edema / etiology
Male
Ophthalmoscopy
Pilot Projects
Protein C / administration & dosage*
Recombinant Proteins / administration & dosage
Retinal Vein Occlusion / complications
Retinal Vein Occlusion / drug therapy*
Time Factors
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity*

Substances

Fibrinolytic Agents
Protein C
Recombinant Proteins
drotrecogin alfa activated